AARTIPHARM Aarti Pharmalabs Q3 FY26 results (Oct–Dec 2025) and concall
Aarti Pharmalabs reported a challenging Q3 FY26 with revenue, EBITDA, and PAT declining YoY, partly due to ₹49 crores of goods in transit not being booked and initial operational hiccups at the new Atali plant. Despite these near-term pressures and softness in the API business, the company declared an interim dividend of ₹1.5 per share. Management remains confident in long-term growth, driven by increasing commercial CDMO projects, new API launches, and the Xanthine expansion, with corrective actions at Atali expected by Q4 FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 19.7%, net profit down 35.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 458 | 538 | 564 | 386 | 418 −9% | 432 −20% |
| EBITDA | 94 | 129 | 146 | 93 | 74 −21% | 102 −21% |
| Net profit | 55 | 74 | 88 | 50 | 28 −49% | 48 −35% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
